Jasmine Trevino
Family · Houston, TXNPI 1013362508
Payments from drug & device makers
Across 212 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$907
- AbbVie$707
- Johnson & Johnson$547
- Lilly USA, LLC$288
- AstraZeneca$263
- UCB, Inc.$262
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,24897%
- Education$1453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 46 | $907 |
| AbbVie | 48 | $707 |
| Johnson & Johnson | 19 | $547 |
| Lilly USA, LLC | 12 | $288 |
| AstraZeneca | 9 | $263 |
| UCB, Inc. | 12 | $262 |
| Boehringer Ingelheim | 11 | $257 |
| Pfizer | 12 | $222 |
| GSK | 10 | $196 |
| Novartis | 9 | $176 |
| Mallinckrodt Hospital Products Inc. | 6 | $169 |
| Aurinia Pharma U.S., Inc. | 6 | $161 |
| Genentech USA, Inc. | 6 | $114 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Almatica Pharma LLC | 1 | $25 |
| Radius Health, Inc. | 1 | $20 |
How this compares
$4,392 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 25 | $182,507 |
| RinvoqUpadacitinib | 15 | $106,043 |
| Xeljanz XrTofacitinib Citrate | 17 | $103,615 |
| Hydroxychloroquine Sulfate | 565 | $14,858 |
| Leflunomide | 86 | $2,704 |
| MethotrexateMethotrexate Sodium | 131 | $2,699 |
| Mycophenolate Mofetil | 33 | $2,498 |
| Prednisone | 306 | $2,206 |
| Cevimeline Hcl | 14 | $1,866 |
| Pilocarpine Hcl | 29 | $1,796 |
| Duloxetine Hcl | 67 | $963 |
| Sulfasalazine | 38 | $955 |
| Gabapentin | 72 | $897 |
| Celecoxib | 68 | $854 |
| Pregabalin | 19 | $746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $707 | $106,04315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.